---
title: "Maco-B Biopharma Climbs 5% On Second Trading Day"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290791924.md"
description: "Maco-B Biopharma gains over 5% in second trading session after surging 103% on debut, reaching fresh high."
datetime: "2026-06-25T07:30:56.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290791924.md)
  - [en](https://longbridge.com/en/news/290791924.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290791924.md)
---

# Maco-B Biopharma Climbs 5% On Second Trading Day

Maco-B Biopharma (2335.HK) climbed more than 5% during Hong Kong trading to **HKD38.86**.

The stock debuted yesterday at the **HKD18.2** IPO price, closing up approximately **103%** to **HKD36.9**. Today marks the second trading day as prices continued higher, touching a new listing high of **HKD39.42** intraday.

As the first northwest China innovative drug company listed under Rule 18A, the firm focuses on peptide therapeutics with its core product MT1013 in Phase III clinical trials. The IPO public offering was oversubscribed by approximately **1,181 times**, with pre-market trading previously gaining over **95%**.

### Related Stocks

- [02335.HK](https://longbridge.com/en/quote/02335.HK.md)

## Related News & Research

- [Globe sustains CDP Supplier Engagement 'A' rating, continuing its collaborative journey across the value chain](https://longbridge.com/en/news/290751646.md)
- [Fortress says Coronation Asset Management raises beneficial stake in Fortress B shares to 20%](https://longbridge.com/en/news/290844550.md)
- [Norges Bank cuts Holmen B stake to 4.81% from 5% threshold](https://longbridge.com/en/news/290830168.md)
- [B Capital leads equity investment in Cadence](https://longbridge.com/en/news/290838536.md)
- [Norges Bank lifts Holmen B stake above 5% to 7,714,121 shares](https://longbridge.com/en/news/290664897.md)